Saroglitazar for Primary biliary cholangitis
The FDA is expected to decide on Saroglitazar for Primary biliary cholangitis by November 27, 2026, under a NDA from Zydus Therapeutics.
What is being decided
Zydus Therapeutics has a NDA under FDA review for Saroglitazar in Primary biliary cholangitis. Dual PPAR agonist under priority review for second-line PBC.
Who this decision matters to
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease in which the immune system mistakenly attacks the small bile ducts in the liver, leading to bile duct destruction and progressive liver damage. The condition predominantly affects middle-aged women and progresses slowly, ultimately leading to cirrhosis and liver failure if untreated. PBC is characterized by elevated cholestasis markers and presence of antimitochondrial antibodies.
Prevalence: Approximately 0.6 per 100,000 to 35 per 100,000 people globally depending on region; higher in northern Europe and North America. See our full Primary Biliary Cholangitis page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Primary Biliary Cholangitis treatment stands today
Research in Primary Biliary Cholangitis is advancing treatment options for patients who don't respond well to traditional ursodeoxycholic acid therapy. Farnesoid X receptor agonists, FGF21 analogs, and immunomodulatory agents are being tested to slow disease progression and prevent liver fibrosis. Trials carefully measure how well treatment works using liver enzyme levels, imaging studies of liver stiffness, and importantly, patient survival without needing transplantation. Understanding whether you respond to standard UDCA therapy helps determine which newer agents might benefit you most. Combination approaches pairing UDCA with emerging therapies are increasingly studied. Biomarkers that predict which patients will respond to specific treatments are helping guide personalized medicine approaches. Your baseline disease stage affects trial eligibility and expected outcomes.
Meanwhile, 69 Primary Biliary Cholangitis trials are recruiting
Whatever the FDA decides here, research on Primary Biliary Cholangitis does not stop. A few currently enrolling studies, US sites first:
Get notified when new primary-biliary-cholangitis trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Saroglitazar?
The FDA's target decision date (PDUFA date) for Saroglitazar in Primary biliary cholangitis is November 27, 2026, disclosed by Zydus Therapeutics. The agency can act before this date and occasionally runs past it.
What is Saroglitazar being reviewed for?
Zydus Therapeutics submitted a NDA for Saroglitazar in Primary biliary cholangitis. Dual PPAR agonist under priority review for second-line PBC.
What happens after the Saroglitazar decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Zydus announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.